Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cell Derived Exome for Diabetic Foot
NCT06480123Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Aug 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in diabetic foot disease (DFD), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Safety of the treatment at 6 months and Efficacy of the treatment at 6 months. Planned start Aug 2024; status: not yet recruiting.
02
Conditions
diabetic foot disease (DFD)
Beyond the preview
Go deeper on NCT06480123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480123.